Metabolic syndrome have the damages on tissues and organs in heart、kindey and vessels. In this study, prospective randomized, controlled, parallel designed ,different doses of Astragalus Mongolia, Gansu Longxi produce treat on the MS patients, and then use real-time quantitative PCR and Western Blotting to detect the index of oxidative stress 、angiotensin-converting enzyme 2 mRNA expression and proteins.

Inclusion Criteria:

1. age 18 years or older, meet the diagnostic criteria of MS
2. non-allergic with the astragalus
3. agree to conduct clinical trials and those who signed the informed consent

Exclusion Criteria:

1. patients with resistant hypertension
2. renal disease requiring dialysis
3. heart failure NYHA ⅢorⅣ;
4. complications of diabetes
5. arteritis
6. cancer
7. thyroid disease
8. unstable coronary heart disease
9. peripheral vascular disease
10. acute cerebral vascular disease11.pregnancy、 planned pregnancy
11. patients with anti-oxidants
12. acute infection
13. other organic dysfunction, such as the liver, respiratory system, blood system, and other rheumatic diseases.